Bloomberg News

Janssen’s Topamax Users Blame Seizure Drug for Birth Defects (1)

October 15, 2013

Johnson & Johnson’s (JNJ:US) Janssen Pharmaceuticals failed to inform expectant mothers of risks that its epilepsy drug Topamax could cause birth defects, a lawyer for the mother of a Virginia 6-year-old told a jury.

April Czimmer wouldn’t have taken Topamax for more than six months had she known the risks associated with the drug, her attorney Tommy Fibich said in opening statements today in state court in Philadelphia.

Czimmer blames the drug for her son’s cleft palate and lip and claims Janssen negligently failed to inform patients about its risks until the U.S. Food and Drug Administration ordered stronger warnings in 2011.

“It is the pharmaceutical equivalent of a drive-by shooting,” Fibich said. “The pharmaceutical company, when they put this drug out into the market knowing it has these causes, they don’t know who it’s going to hit.”

Janssen said in court papers that it isn’t liable for the boy’s injuries. Topamax came with FDA-approved prescribing information that adequately set forth warnings and precautions associated with its use, the company said.

The company is facing the first two of 63 cases over the seizure drug this month in Philadelphia. Topamax, approved by the FDA in 1996, was one of New Brunswick, New Jersey-based J&J’s top sellers before it lost patent protection in 2009 and sales (JNJ:US) plummeted 58 percent to $1.15 billion, according to the company’s annual report.

Migraine Treatment

Czimmer said she was prescribed Topamax from August 2006 through February 2007 to treat migraines. Her son Blake was born in September 2007 with defects requiring four surgeries since birth, Fibich said.

The FDA on March 4, 2011, said preliminary studies suggested Topamax might contribute to cleft lips and cleft palates in infants born to women who used the medication during pregnancy. The government asked the company to update the label enclosed with the medicine to reflect a stronger classification and warning for the drug.

The birth defects, known as oral clefts, occur when parts of the lip or palate do not completely fuse together in the first trimester of pregnancy, the FDA said. The defects range from a small notch in the lip to a groove that runs into the roof of the mouth and nose. The condition, which can lead to ear infections and problems with eating and talking, often requires surgery to close the lip and palate.

Raise Risks

Lawyers for mothers who took the drug during pregnancy claim Janssen knew as early as 2002 that Topamax could raise the risk of birth defects, according to a master complaint filed in September 2011.

They claim the company and its predecessor (JNJ:US), Ortho-McNeil Pharmaceutical, promoted Topamax for off-label use since at least 2001. The off-label uses included weight loss, anxiety disorders, cluster headaches, sleep apnea, diabetes and substance abuse, according to court papers.

Janssen aggressively advertised and sold Topamax for these off-label uses “without any valid scientific evidence” that supported the use of the drug for the treatment of such ailments, according to the master complaint.

The company hired outside physicians to promote the drug for off-label use and implemented programs such as “Doctor-For-a-Day,” in which physicians accompanied sales representatives on calls to push the drug.

Criminal Case

In April 2010, J&J paid $81 million to resolve criminal and civil cases over illegal promotion of the drug. A month later, Ortho-McNeil admitted that it illegally marketed Topamax and pleaded guilty to a misdemeanor charge of selling a misbranded drug as part of the settlement.

Judge Arnold New, who is overseeing the lawsuits in Philadelphia, granted Janssen’s request to bar punitive damages in the case. He also dismissed an accusation that Janssen failed to warn patients and claims that the drug was defective in design, according to a July 16 court order. The trial is going forward on claims of negligence, fraud and misrepresentation.

The case is Czimmer v. Janssen Pharmaceuticals Inc., 110503459, Court of Common Pleas, Philadelphia County, Pennsylvania. The master case is In Re Topamax Litigation, 110602131, Court of Common Pleas, Philadelphia County, Pennsylvania.

To contact the reporter on this story: Sophia Pearson in Philadelphia at spearson3@bloomberg.net

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net


Soul Searcher
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

Companies Mentioned

  • JNJ
    (Johnson & Johnson)
    • $99.2 USD
    • 2.06
    • 2.08%
Market data is delayed at least 15 minutes.
 
blog comments powered by Disqus